

UTILITY PATENT APPLICATION TRANSMITTAL

(Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
PB0178

Total Pages in this Submission
170

TO THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application
Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

Human Posh-Like Protein 1

J1011 U.S. PRO
10/06/2001
01/30/02

and invented by:

Mark Shannon

If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information:

Continuation Divisional Continuation-in-part (CIP) of prior application No.:

Which is a:

Continuation Divisional Continuation-in-part (CIP) of prior application No.:

Which is a:

Continuation Divisional Continuation-in-part (CIP) of prior application No.:

Enclosed are:

Application Elements

1. Filing fee as calculated and transmitted as described below
2. Specification having 144 pages and including the following:
 - a. Descriptive Title of the Invention
 - b. Cross References to Related Applications (if applicable)
 - c. Statement Regarding Federally-sponsored Research/Development (if applicable)
 - d. Reference to Sequence Listing, a Table, or a Computer Program Listing Appendix
 - e. Background of the Invention
 - f. Brief Summary of the Invention
 - g. Brief Description of the Drawings (if filed)
 - h. Detailed Description
 - i. Claim(s) as Classified Below
 - j. Abstract of the Disclosure

UTILITY PATENT APPLICATION TRANSMITTAL
(Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.

PB0178

Total Pages in this Submission

170

Application Elements (Continued)

3. Drawing(s) (when necessary as prescribed by 35 USC 113)
a. Formal Number of Sheets _____
b. Informal Number of Sheets 11

4. Oath or Declaration
a. Newly executed (original or copy) Unexecuted
b. Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)
c. With Power of Attorney Without Power of Attorney
d. DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application,
see 37 C.F.R. 1.63(d)(2) and 1.33(b).

5. Incorporation By Reference (usable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under
Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby
incorporated by reference therein.

6. CD ROM or CD-R in duplicate, large table or Computer Program (Appendix)

7. Application Data Sheet (See 37 CFR 1.76)

8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)
a. Computer Readable Form (CRF)
b. Specification Sequence Listing on:
i. CD-ROM or CD-R (2 copies); or
ii. Paper
c. Statement(s) Verifying Identical Paper and Computer Readable Copy

Accompanying Application Parts

9. Assignment Papers (cover sheet & document(s))

10. 37 CFR 3.73(B) Statement (when there is an assignee)

11. English Translation Document (if applicable)

12. Information Disclosure Statement/PTO-1449 Copies of IDS Citations

13. Preliminary Amendment

14. Return Receipt Postcard (MPEP 503) (Should be specifically itemized)

15. Certified Copy of Priority Document(s) (if foreign priority is claimed)

16. Certificate of Mailing
 First Class Express Mail (Specify Label No.): EL 717697854 US

UTILITY PATENT APPLICATION TRANSMITTAL
(Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
PB0178

Total Pages in this Submission
170

Accompanying Application Parts (Continued)

17. Additional Enclosures (please identify below):

Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)

18. Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.

Warning

An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
PB0178

Total Pages in this Submission
170

Fee Calculation and Transmittal


CLAIMS AS FILED

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	62	- 20 =	42	x \$18.00	\$756.00
Indep. Claims	6	- 3 =	3	x \$84.00	\$252.00
Multiple Dependent Claims (check if applicable)		☒			\$280.00
				BASIC FEE	\$740.00
OTHER FEE (specify purpose)					\$0.00
				TOTAL FILING FEE	\$2,028.00

A check in the amount of **\$2,028.00** to cover the filing fee is enclosed.

The Commissioner is hereby authorized to charge and credit Deposit Account No. **500-588** as described below. A duplicate copy of this sheet is enclosed.

- Charge the amount of **\$2,028.00** as filing fee.
- Credit any overpayment.
- Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
- Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).



Stephen G. Ryan
Amersham Biosciences Corp.
800 Centennial Avenue
Piscataway, New Jersey 08855

Dated: **January 30, 2002**

CC:

(732) 457-8071
Reg. No.: 39,015

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)Applicant(s): **M. Shannon**

Docket No.

PB0178Serial No.
To be assignedFiling Date
January 30, 2002Examiner
To be assignedGroup Art Unit
To be assignedInvention: **Human Posh-Like Protein 1**

I hereby certify that the following correspondence:

transmittal letter (4 pages) with copy, filing fee, specification (144 pages), 62 claims, 11 drawing sheets, executed combined Declaration and Power of Attorney, sequence listing with required statements, three (3) compact discs, and a return postcard*(Identify type of correspondence)*

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on

January 30, 2002*(Date)***Melissa Leck***(Typed or Printed Name of Person Mailing Correspondence)**(Signature of Person Mailing Correspondence)***EL 717697854 US***("Express Mail" Mailing Label Number)*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: M. Shannon Group Art Unit: To be assigned
Serial Number: To be assigned Examiner: To be assigned
Filed: January 30, 2002
For: Human Posh-Like Protein 1

Submission of Nucleotide and/or Amino Acid Sequence Listing

Assistant Commissioner for Patents
Box: New Patent Application
Washington, D.C. 20231

Sir:

In connection with the captioned application, the disclosure enclosed herewith,
Applicants submit the following items:


- 1) Sequence Listing in CRF filed on CD-R pursuant to 37 C.F.R. § 1.824.
- 2) Written sequence listing filed on CD-R pursuant to 37 C.F.R. § 1.52(e)(1)(ii). The disc is provided in duplicate (COPY 1, COPY 2). The two copies are identical, with each disc formatted for IBM-PC, MS-WindowsNT operating system compatibility, each disc identically containing a single file named pto_PB0178.txt, having 594 kilobytes, last modified on January 17, 2002, and recorded January 24, 2002.
- 3) Required statements:
 - A. Applicants aver that the sequence listings do not include any new matter.

B. Applicants aver that that sequence listing information recorded in computer readable form is identical to the written (on compact disc) sequence listing.

Please direct any remaining issues to Applicant's counsel at the telephone number provided below.

Amersham Biosciences
P.O. Box 1327
800 Centennial Avenue
Piscataway, New Jersey 08855-1327
(732)457-8071 (voice)
(732)457-8463 (facsimile)

Respectfully submitted,



Stephen G. Ryan
Reg. No. 39,015